Intelligence · Clinical Development
Pipeline search results
Programs matching “gemcitabine” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 50 pipeline programs matching "gemcitabine" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
2020HXFH037
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
AFMMUChina
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
Docetaxel+lobaplatin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lobaplatin and Gemcitabine in Combination, Second-line Treatments on Advanced Osteosarcoma
1 trial -
GEMCITABINE for Patients with histologically or…
AstraZeneca AB
Patients with histologically or cytologically documented muscle-invasive transitional cell carcinoma (TCC) of the bladder
1 trial -
Gemcitabine
AstraZeneca
Biliary Tract Cancer
1 trial -
Gemcitabine,Cisplatin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
Irinotecan liposome、5-Fluorouracil、Leucovorin
Jian Li
Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy
1 trial -
NDV-01 (sustained-release gemcitabine-docetaxel)
RELMADA THERAPEUTICS, INC.
Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
1 trial -
NDV-01 (sustained-release gemcitabine-docetaxel)
RELMADA THERAPEUTICS, INC.
Bladder (Urothelial, Transitional Cell) Cancer
2 trials -
gemcitabine
NORTHWEST BIOTHERAPEUTICS INC
Non-Small Cell Lung Cancer
1 trial -
gemcitabine and cisplatin (Induction chemotherapy)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
gemcitabine and cisplatin (Induction chemotherapy)
Sun Yat-sen University
Nasopharyngeal Carcinoma
1 trial -
12.5mg sunitinib with Cisplatin and Gemcitabine
Hospital Authority, Hong Kong
Nasopharyngeal Carcinoma
1 trial -
2021-SR-545
The First People's Hospital of Lianyungang
Lymphoma, Large B-Cell, Diffuse
1 trial -
2023-SR-002
The First People's Hospital of Lianyungang
NK-T-Cell Lymphoma, Extranodal
1 trial -
AK112-210
Akeso
Metastatic Pancreatic Ductal Adenocarcinoma
1 trial -
Atu027 & gemcitabine in lead in safety period
Silence Therapeutics plc
Carcinoma, Pancreatic Ductal
1 trial -
Cemiplimab Plus Gemcitabine
Regeneron UK Limited
Pancreatic Ductal Adenocarcinoma (mPDAC)
1 trial -
GEMCITABINE
Wuhan Createrna Science and Technology Co., Ltd
Upper Tract Urothelial Carcinoma. Upper urinary tract transitional cell carcinoma
1 trial -
Gemcitabine
Regeneron UK Limited
Bladder Cancer
1 trial -
Gemcitabine
Arcus Biosciences
Biliary Tract Carcinoma
1 trial -
Gemcitabine
HALOZYME THERAPEUTICS, INC.
Stage IV Pancreatic Cancer
1 trial -
Gemcitabine
LEXICON PHARMACEUTICALS, INC.
Locally Advanced Unresectable Pancreatic Adenocarcinoma
1 trial -
Gemcitabine
Compass Therapeutics
Metastatic Biliary Tract Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.